CO2019001402A2 - Método para prevenir o tratar la pérdida de la audición - Google Patents

Método para prevenir o tratar la pérdida de la audición

Info

Publication number
CO2019001402A2
CO2019001402A2 CONC2019/0001402A CO2019001402A CO2019001402A2 CO 2019001402 A2 CO2019001402 A2 CO 2019001402A2 CO 2019001402 A CO2019001402 A CO 2019001402A CO 2019001402 A2 CO2019001402 A2 CO 2019001402A2
Authority
CO
Colombia
Prior art keywords
hearing loss
prevent
treat hearing
preventing
methods
Prior art date
Application number
CONC2019/0001402A
Other languages
English (en)
Inventor
Alexander Bausch
Original Assignee
Support Venture Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Support Venture Gmbh filed Critical Support Venture Gmbh
Publication of CO2019001402A2 publication Critical patent/CO2019001402A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con métodos para prevenir o tratar la pérdida de audición y métodos para prevenir o inhibir la degeneración de células ciliadas o la muerte de células ciliadas en un sujeto.
CONC2019/0001402A 2016-08-17 2019-02-15 Método para prevenir o tratar la pérdida de la audición CO2019001402A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16184541 2016-08-17
PCT/EP2017/070683 WO2018033543A1 (en) 2016-08-17 2017-08-15 Method of preventing or treating hearing loss

Publications (1)

Publication Number Publication Date
CO2019001402A2 true CO2019001402A2 (es) 2019-02-19

Family

ID=56740115

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0001402A CO2019001402A2 (es) 2016-08-17 2019-02-15 Método para prevenir o tratar la pérdida de la audición

Country Status (18)

Country Link
US (1) US20190209568A1 (es)
EP (1) EP3500258A1 (es)
JP (1) JP2019528273A (es)
KR (1) KR20190039142A (es)
CN (1) CN109562105A (es)
AU (1) AU2017313296A1 (es)
BR (1) BR112019003006A2 (es)
CA (1) CA3033887A1 (es)
CL (1) CL2019000410A1 (es)
CO (1) CO2019001402A2 (es)
EA (1) EA201990220A1 (es)
IL (1) IL264625A (es)
MA (1) MA45981A (es)
MX (1) MX2019001819A (es)
PE (1) PE20190421A1 (es)
PH (1) PH12019550015A1 (es)
SG (1) SG11201900776TA (es)
WO (1) WO2018033543A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012775SA (en) * 2018-07-13 2021-02-25 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
US20020151491A1 (en) * 2000-11-28 2002-10-17 Jian-Dong Li Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC
HU229604B1 (en) 2001-02-12 2014-02-28 Hoffmann La Roche 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them
DE602004005238T2 (de) 2003-11-13 2007-11-08 F. Hoffmann-La Roche Ag Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7-one
WO2005115527A2 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
CN101679211A (zh) 2007-06-15 2010-03-24 霍夫曼-拉罗奇有限公司 用于制备3-氨基-戊-1,5-二醇的新方法
KR20170117083A (ko) * 2015-02-11 2017-10-20 서포트-벤처 게엠베하 난청을 예방 또는 치료하는 방법
MY195671A (en) * 2016-06-08 2023-02-03 Support Venture Gmbh Pharmaceutical Combinations for Treating Cancer

Also Published As

Publication number Publication date
MA45981A (fr) 2019-06-26
PE20190421A1 (es) 2019-03-19
JP2019528273A (ja) 2019-10-10
WO2018033543A1 (en) 2018-02-22
CL2019000410A1 (es) 2019-06-28
PH12019550015A1 (en) 2019-07-24
EA201990220A1 (ru) 2019-08-30
IL264625A (en) 2019-02-28
EP3500258A1 (en) 2019-06-26
US20190209568A1 (en) 2019-07-11
CN109562105A (zh) 2019-04-02
SG11201900776TA (en) 2019-03-28
BR112019003006A2 (pt) 2019-05-14
KR20190039142A (ko) 2019-04-10
CA3033887A1 (en) 2018-02-22
MX2019001819A (es) 2019-06-13
AU2017313296A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
CO2017008129A2 (es) Método para prevenir o tratar la pérdida de la audición
PH12019502724A1 (en) Compositions for modulating c9orf72 expression
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
ZA201906236B (en) Kits and methods for treating hair
HK1258825A1 (zh) 用於治療多汗症的方法和組合物
PL3402575T4 (pl) Sposoby i kompozycje do traktowania zniszczonych włosów
EP3519058C0 (en) HAIR TREATMENT COMPOSITIONS AND METHODS
ZA201900044B (en) Tuberculosis compositions and methods of treating or preventing tuberculosis
HK1246791A1 (zh) 用於預防或治療感覺毛細胞死亡的化合物和方法
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
BR112018013269A2 (pt) composições e métodos para a avaliação do risco de ocorrência do câncer
MX2021006326A (es) Inhibidores de pcna.
HK1243635A1 (zh) 治療皮膚病況的組合物和方法
BR112017008097A2 (pt) método para tratar condições oculares
IL290810A (en) Agents for stem cell differentiation and cancer treatment
CO2019001402A2 (es) Método para prevenir o tratar la pérdida de la audición
IL244247A0 (en) Means and method for managing an investment portfolio
UA106529U (uk) Спосіб терапії променевих опіків шкіри